Search by Drug Name or NDC

NDC 55513-0956-01 Vectibix 400 mg/20mL Details

Vectibix 400 mg/20mL

Vectibix is a INTRAVENOUS SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Amgen Inc. The primary component is PANITUMUMAB.

MedlinePlus Drug Summary

Panitumumab is used to treat a type of cancer of the colon or rectum that has spread to other areas of the body either during or after treatment with other chemotherapy drugs. Panitumumab is in a class of medications called monoclonal antibodies. It works by slowing or stopping the growth of cancer cells.

Related Packages: 55513-0956-01
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Panitumumab Injection

Product Information

NDC	55513-0956
Product ID	55513-956_59928d12-bde9-4433-8316-a142514ef952
Associated GPIs	21360070002035
GCN Sequence Number	064359
GCN Sequence Number Description	panitumumab VIAL 400MG/20ML INTRAVEN
HIC3	V1W
HIC3 Description	ANTINEOPLASTIC EGF RECEPTOR BLOCKER MCLON ANTIBODY
GCN	13639
HICL Sequence Number	034054
HICL Sequence Number Description	PANITUMUMAB
Brand/Generic	Brand
Proprietary Name	Vectibix
Proprietary Name Suffix	n/a
Non-Proprietary Name	panitumumab
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	SOLUTION
Route	INTRAVENOUS
Active Ingredient Strength	400
Active Ingredient Units	mg/20mL
Substance Name	PANITUMUMAB
Labeler Name	Amgen Inc
Pharmaceutical Class	Antibodies, Monoclonal [CS], Epidermal Growth Factor Receptor Antagonist [EPC], HER1 Antagonists [MoA]
DEA Schedule	n/a
Marketing Category	BLA
Application Number	BLA125147
Listing Certified Through	2024-12-31

Package

NDC 55513-0956-01 (55513095601)

Pricing Information	N/A
NDC Package Code	55513-956-01
Billing NDC	55513095601
Package	1 VIAL, SINGLE-DOSE in 1 CARTON (55513-956-01) / 20 mL in 1 VIAL, SINGLE-DOSE
Marketing Start Date	2006-10-10
NDC Exclude Flag	N